Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Argenx Se ADR (NQ: ARGX )

543.84 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 543.84
Bid (Size) 460.00 (1)
Ask (Size) 555.00 (3)
Prev. Close 543.84
Today's Range 543.84 - 543.84
52wk Range 327.73 - 554.74
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Latest Analyst Ratings For argenx
Via Benzinga
argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions
From argenx SE
Via GlobeNewswire

Performance

YTD
+42.74%
+42.74%
1 Month
+4.14%
+4.14%
3 Month
+16.56%
+16.56%
6 Month
+51.74%
+51.74%
1 Year
+10.90%
+10.90%

More News

Read More
Biotech Stocks : Are You A Trader Or A Longer Term Investor?
Via Talk Markets
Peeling Back The Layers: Exploring argenx Through Analyst Insights
Via Benzinga
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases
Via Investor's Business Daily
What 25 Analyst Ratings Have To Say About argenx
Via Benzinga
The Analyst Verdict: argenx In The Eyes Of 27 Experts
Via Benzinga
Snowflake, Hawaiian Electric Industries And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy
From argenx SE
Via GlobeNewswire
Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
Via Benzinga
Exposures Product Safety
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
This CrowdStrike Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Via Benzinga
Northrop Grumman To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
From argenx SE
Via GlobeNewswire
argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024
From argenx SE
Via GlobeNewswire
argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
From argenx SE
Via GlobeNewswire
Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
From Zai Lab Limited
Via Business Wire
argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting
From argenx SE
Via GlobeNewswire
Why Is European Drugmaker Argenx Stock Trading Higher On Monday?
Via Benzinga
Exposures Product Safety
Argenx Surges After Its Bread-And-Butter Drug Wins Another FDA Approval
Via Investor's Business Daily
Exposures Product Safety
Micron To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
From argenx SE
Via GlobeNewswire
argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024
From argenx SE
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.